UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 4.511

Sortiert nach

Synthetic studies on the indane SHIP1 agonist AQX-1125

Organic & biomolecular chemistry, 2022-05, Vol.2 (19), p.416-42

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome

The Journal of urology, 2016-09, Vol.196 (3), p.747-754

2016

Link zum Volltext

Verfügbarkeit prüfen

AQX‐1125, small molecule SHIP1 activator inhibits bleomycin‐induced pulmonary fibrosis

British journal of pharmacology, 2017-09, Vol.174 (18), p.3045-3057

2017

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo

British journal of pharmacology, 2013-03, Vol.168 (6), p.1506-1518

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo

British journal of pharmacology, 2013-03, Vol.168 (6), p.1519-1529

2013

Link zum Volltext

Verfügbarkeit prüfen

The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma

Clinical and experimental allergy, 2014-09, Vol.44 (9), p.1146-1153

2014

Link zum Volltext

Verfügbarkeit prüfen

SHIP1 Activator AQX-1125 Regulates Osteogenesis and Osteoclastogenesis Through PI3K/Akt and NF-κb Signaling

Frontiers in cell and developmental biology, 2022-04, Vol.10, p.826023-826023

2022

Link zum Volltext

Verfügbarkeit prüfen

MP39-13 AN OPEN-LABEL, TWO-PART, SEQUENTIAL DOSE STUDY ASSESSING THE ABSOLUTE BIOAVAILABILITY, MASS BALANCE, AND RECOVERY FOR [14C]-ROSIPTOR (AQX-1125) IN HEALTHY SUBJECTS

The Journal of urology, 2018-04, Vol.199 (4), p.e515-e515

2018

Link zum Volltext

Verfügbarkeit prüfen

P32 - Comparative metabolism of 14C-AQX-1125 following oral administration to rats, dogs and humans

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S30-S31

2020

Link zum Volltext

Verfügbarkeit prüfen

P31 - Rates and routes of excretion of 14C-AQX-1125 following oral administration to rats, dogs and humans

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S30-S30

2020

Link zum Volltext

Verfügbarkeit prüfen

MP24-16 PLASMA AND URINARY PHARMACOKINETICS OF A NOVEL, ORAL SHIP1 ACTIVATOR AQX-1125 IN FEMALE PATIENTS WITH INTERSTITIAL CYSTITIS

The Journal of urology, 2016-04, Vol.195 (4), p.e276-e276

2016

Link zum Volltext

Verfügbarkeit prüfen

MP72-17 EFFECT OF AQX-1125 ON URINARY BLADDER INFLAMMATION AND PAIN INDUCED BY CYCLOPHOSPHAMIDE IN RATS, BY TARGETING THE SHIP1 PATHWAY

The Journal of urology, 2016-04, Vol.195 (4), p.e958-e958

2016

Link zum Volltext

Verfügbarkeit prüfen

D37 COPD: DEVELOPMENTAL THERAPEUTICS: Safety And Efficacy Of Aqx-1125 In Chronic Obstructive Pulmonary Disease (COPD) - Results Of The Phase 2 Flagship Study

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Link zum Volltext

Verfügbarkeit prüfen

The effects of the novel SHIP 1 activator AQX ‐1125 on allergen‐induced responses in mild‐to‐moderate asthma

Clinical and experimental allergy, 2014-09, Vol.44 (9), p.1146-1153

2014

Link zum Volltext

Verfügbarkeit prüfen

B39 COPD EXACERBATIONS: PRECIPITATING FACTORS, PREVENTION, AND OUTCOME: The Flagship Study: A 12-Week Phase Ii Study To Evaluate The Efficacy And Safety Of Aqx-1125 Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (COPD) By Targeting The Ship1 Pathway

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models

British journal of pharmacology, 2013-02, Vol.168 (6), p.1519-1529

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis

British journal of pharmacology, 2013-02, Vol.168 (6), p.1506-1518

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

British journal of pharmacology, 2013-03, Vol.168 (6), p.1506-1518

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

British journal of pharmacology, 2013-03, Vol.168 (6), p.1519-1529

2013

Link zum Volltext

Verfügbarkeit prüfen

Serum antibody responses in horses and mice following immunization with Actinobacillus equuli outer membrane proteins and recombinant Aqx toxin

The veterinary journal (1997), 2011-11, Vol.190 (2), p.e91-e94

2011

Link zum Volltext

Verfügbarkeit prüfen

AQX-1125, a Modulator of the SHIP1/PI3K Pathway, Suppresses Chemotaxis and Inflammation

Journal of allergy and clinical immunology, 2011-02, Vol.127 (2), p.AB65-AB65

2011

Link zum Volltext

Verfügbarkeit prüfen

Small Molecule SHIP Agonist AQX-MN100 Inhibits Multiple Myeloma (MM) Cell Growth In NOD/SCID Mice and Reduces Immune Suppressive Myeloid Derived Suppressor Cells (MDSC) and Regulatory T Cells (Tregs) In Mouse Model

Blood, 2010-11, Vol.116 (21), p.792-792

2010

Link zum Volltext

Verfügbarkeit prüfen

Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC)

Expert opinion on investigational drugs, 2016-05, Vol.25 (5), p.521-529

2016

Link zum Volltext

Verfügbarkeit prüfen

Serum antibodies in mares and foals to Actinobacillus equuli whole cells, outer membrane proteins, and Aqx toxin

Veterinary Immunology and Immunopathology, 2007-08, Vol.118 (3), p.310-316

2007

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Aqx and its operon: the hemolytic RTX determinant of Actinobacillus equuli

Veterinary microbiology, 2002-06, Vol.87 (2), p.159-174

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 4.511

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.360)
Mit Volltextzugriff
(4.227)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
(1.892)
Journals@Ovid Ovid Full Text
(979)
Single Journals
(889)
Oxford Journals Current Collection
(692)
Oxford Journals 2020 Medicine
(666)
IngentaConnect
(612)
JSTOR Archive Collection A-Z Listing
(604)
Springer Online Journals Complete
(477)
eBooks on EBSCOhost
(380)
Ebook Central Perpetual and DDA
(363)
De Gruyter journals
(349)
IngentaConnect Journals
(332)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(331)
De Gruyter eBooks
(241)
Nexis Uni
(189)
Factiva
(187)
Wiley Online Library All Journals
(144)
Springer Books
(118)
Business Source Ultimate
(101)
Wiley Online Library Full Collection 2018
(95)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

American Journal Of Clinical Pathology
(661)
Hermes
(243)
Philologus
(195)
Glotta
(80)
Klio
(72)
Athenaeum
(62)
The Times Educational Supplement
(55)
Mnemosyne
(54)
Rivista Di Filologia E Di Istruzione Classica
(47)
Balkan Studies
(38)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Synthetic studies on the indane SHIP1 agonist AQX-1125

A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome

AQX‐1125, small molecule SHIP1 activator inhibits bleomycin‐induced pulmonary fibrosis

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo

The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma

SHIP1 Activator AQX-1125 Regulates Osteogenesis and Osteoclastogenesis Through PI3K/Akt and NF-κb Signaling

MP39-13 AN OPEN-LABEL, TWO-PART, SEQUENTIAL DOSE STUDY ASSESSING THE ABSOLUTE BIOAVAILABILITY, MASS BALANCE, AND RECOVERY FOR [14C]-ROSIPTOR (AQX-1125) IN HEALTHY SUBJECTS

P32 - Comparative metabolism of 14C-AQX-1125 following oral administration to rats, dogs and humans

P31 - Rates and routes of excretion of 14C-AQX-1125 following oral administration to rats, dogs and humans

MP24-16 PLASMA AND URINARY PHARMACOKINETICS OF A NOVEL, ORAL SHIP1 ACTIVATOR AQX-1125 IN FEMALE PATIENTS WITH INTERSTITIAL CYSTITIS

MP72-17 EFFECT OF AQX-1125 ON URINARY BLADDER INFLAMMATION AND PAIN INDUCED BY CYCLOPHOSPHAMIDE IN RATS, BY TARGETING THE SHIP1 PATHWAY

D37 COPD: DEVELOPMENTAL THERAPEUTICS: Safety And Efficacy Of Aqx-1125 In Chronic Obstructive Pulmonary Disease (COPD) - Results Of The Phase 2 Flagship Study

The effects of the novel SHIP 1 activator AQX ‐1125 on allergen‐induced responses in mild‐to‐moderate asthma

B39 COPD EXACERBATIONS: PRECIPITATING FACTORS, PREVENTION, AND OUTCOME: The Flagship Study: A 12-Week Phase Ii Study To Evaluate The Efficacy And Safety Of Aqx-1125 Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (COPD) By Targeting The Ship1 Pathway

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

Characterization of AQX‐1125, a small‐molecule SHIP1 activator

Serum antibody responses in horses and mice following immunization with Actinobacillus equuli outer membrane proteins and recombinant Aqx toxin

AQX-1125, a Modulator of the SHIP1/PI3K Pathway, Suppresses Chemotaxis and Inflammation

Small Molecule SHIP Agonist AQX-MN100 Inhibits Multiple Myeloma (MM) Cell Growth In NOD/SCID Mice and Reduces Immune Suppressive Myeloid Derived Suppressor Cells (MDSC) and Regulatory T Cells (Tregs) In Mouse Model

Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC)

Serum antibodies in mares and foals to Actinobacillus equuli whole cells, outer membrane proteins, and Aqx toxin

Characterization of Aqx and its operon: the hemolytic RTX determinant of Actinobacillus equuli

Aktive Filter

Suchergebnisse filtern